Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, Inc. (NASDAQ: ATHA), which has announced a transition to the name LeonaBio, Inc. with a new ticker "LONA," regularly issues news updates as a clinical-stage biopharmaceutical company headquartered in the Seattle, Washington area. Its press releases focus on the development of novel small molecule therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS).
News for ATHA commonly covers progress in the company’s lead programs, lasofoxifene and ATH-1105. Updates include clinical trial milestones such as completion of a first-in-human Phase 1 trial of ATH-1105 in healthy volunteers, presentations of safety, tolerability and pharmacokinetic data, and enrollment status for the Phase 3 ELAINE-3 trial of lasofoxifene in ER+, HER2-negative, ESR1-mutated metastatic breast cancer. The company also reports on preclinical findings for ATH-1105 in ALS models and scientific presentations at major neurology and ALS-focused conferences.
Investors following ATHA news will also see corporate and regulatory developments, including announcements about a 10-for-1 reverse stock split aimed at maintaining Nasdaq listing requirements, notices of regained compliance with the minimum bid price rule, and details of private placement financings intended to support clinical and regulatory milestones. Additional releases describe Athira’s strategic alternatives review and its licensing agreements with Sermonix Pharmaceuticals and Ligand Pharmaceuticals for lasofoxifene.
This news feed provides a centralized view of Athira/LeonaBio’s clinical, scientific and corporate disclosures, allowing readers to track how its oncology and neurology pipelines evolve over time and how financing and licensing arrangements relate to ongoing and planned trials.
Athira Pharma (NASDAQ: ATHA) is hosting a webinar on October 28 at 1 p.m. PT to discuss the P300 testing method's role in assessing cognitive functioning related to Alzheimer's disease. Featured speakers include Larry Ereshefsky and Leen Kawas, who will delve into the P300 latency measurement and its links to cognitive outcomes in patients undergoing ATH-1017 treatment. The event will be accessible via Athira's investor website, with a replay available for 30 days post-event.
Lumen Bioscience announced the appointment of Mark Litton, PhD, MBA, Chief Operating Officer of Athira Pharma (NASDAQ: ATHA), to its Board of Directors. With over two decades in life sciences, including experience as co-founder and Chief Business Officer at Alder BioPharmaceuticals, Dr. Litton brings valuable expertise in strategic growth and financing. Lumen is focused on developing biologic drugs for diseases lacking effective treatments, utilizing innovative drug development technologies aimed at reducing costs and improving access.
Athira Pharma (NASDAQ: ATHA) has commenced patient dosing in its Phase 2/3 clinical trial for ATH-1017, aimed at treating mild-to-moderate Alzheimer’s disease. The trial, named LIFT-AD, will enroll approximately 300 patients in the U.S. and Australia. Previous studies indicated positive effects of ATH-1017 on brain function. This randomized, placebo-controlled trial will evaluate safety and efficacy by measuring cognition and global assessments over a 26-week period. ATH-1017 targets network recovery in the brain, potentially offering new hope for Alzheimer's treatment.
Athira Pharma, a late clinical-stage biopharmaceutical company, has successfully closed its initial public offering of 12 million shares at $17.00 per share, raising gross proceeds of $204 million. Trading commenced on the Nasdaq under the ticker symbol ATHA on September 18, 2020. The underwriters have a 30-day option to purchase an additional 1.8 million shares at the IPO price. The offering was registered with the SEC and became effective on September 17, 2020, with Goldman Sachs, Jefferies, and Stifel acting as joint book-running managers.
Athira Pharma announced the pricing of its IPO, offering 12 million shares at $17.00 each. This move aims to raise gross proceeds of approximately $204 million before expenses. Trading under the ticker symbol ATHA on Nasdaq begins on September 18, 2020, with the offering closing on September 22, 2020, pending customary conditions. The underwriters also received an option to purchase 1.8 million additional shares. Goldman Sachs, Jefferies, and Stifel are managing the offering as joint book-running managers.